GL1X · GenesisL1 explorer

Research workbench

Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4)

Analyse Crystal structure of human transthyretin variant A25T in complex with thyroxine… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3OZK
Type
protein
Length
231 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Transthyretin
UniProt
P02766
Ligands
T44
Pockets
3 · best druggability 0.36

Structure

x-ray diffraction · 2 distinct chains · 6% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATransthyretinprotein1166% helix, 51% strandP02766
BTransthyretinprotein1157% helix, 51% strandP02766

Ligands and binding sites

  • T44 · 3,5,3',5'-tetraiodo-L-thyronine · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1670.360.7816empty
2850.330.7419empty
3630.330.7614empty

Interfaces

1 interface between chains.

  • A–B · 913 Ų buried · 20 hydrogen bonds · protein-protein

Compared structures

  • 3OZK · Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4) · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.